Post Doctoral Researcher at The University Of Kansas, United States
Dr. Sagar Salave is a postdoctoral researcher at the Vaccine Analytics and Formulation Center, University of Kansas, USA, within the Department of Pharmaceutical Chemistry. With a strong foundation in pharmaceutical sciences, Dr. Salave has developed a comprehensive profile combining academic excellence, industrial experience, and innovative research capabilities. His expertise lies in the formulation of advanced drug delivery systems, including mRNA lipid nanoparticles, lyophilized vaccines, ocular therapeutics, and peptide-based nanocarriers. His research contributions span both academia and industry, showcasing an impressive balance between scientific innovation and practical application. Dr. Salave is widely recognized for his impactful work on osteoporosis and vaccine development and holds active editorial roles in several reputed scientific journals.
Profile
Scholar
Education
Dr. Salave earned his Ph.D. in Pharmaceutics from the National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, where he worked on novel drug delivery systems targeting osteoporosis, specifically developing lipid nanocarriers for sustained peptide delivery. Prior to that, he completed his M.S. (Pharm.) from NIPER Hyderabad with research focused on microspheres, liposomes, and hydrogels. He obtained his Bachelor of Pharmacy from Appasaheb Birnale College of Pharmacy, Sangli, Maharashtra, where he laid the groundwork for his career in pharmaceutical formulation and pre-formulation studies. His academic training provided him with robust knowledge in QbD-based development, advanced drug delivery systems, and pharmaceutical analytics.
Experience
Dr. Salave’s experience spans across prestigious academic institutions and the pharmaceutical industry. Currently, at the University of Kansas, he is involved in developing and characterizing mRNA lipid nanoparticle formulations and live viral vaccines, with a strong emphasis on lyophilization and analytical methods. Prior to this, he worked as an FR&D Officer at Ciron Drugs & Pharmaceuticals Pvt. Ltd., Mumbai, where he developed ophthalmic and injectable formulations. His earlier roles at Lupin Limited as a Research Executive and Intern exposed him to the intricacies of formulation scale-up, analytical validation, and plant-level execution. These cumulative experiences have refined his formulation, analytical, and regulatory documentation skills across various dosage forms, making him a versatile pharmaceutical scientist.
Research Interests
Dr. Salave’s research interests lie in the fields of nanomedicine, peptide drug delivery, mRNA therapeutics, vaccine formulation, and ocular drug delivery. He has demonstrated expertise in designing sustained-release peptide-loaded nanocarriers, hybrid systems combining liposomes with hydrogels, and site-specific targeted delivery for bone diseases. His work also extends to characterizing biological responses through cell-based assays and small animal models. Currently, his work focuses on advancing vaccine formulation science, especially the stabilization and delivery of mRNA and viral vaccines via lyophilization technologies. He continues to innovate in developing therapeutics that improve bioavailability, targeting precision, and patient compliance.
Awards
Dr. Salave has received multiple accolades throughout his academic career. Notably, he was awarded financial support under the ‘Student Start-up and Innovation Policy (SSIP)’ at NIPER Ahmedabad for two projects: a long-acting implantable formulation for dry eye disease and a novel herbal mouth ulcer treatment, receiving INR 100,000 and INR 75,000 respectively. Additionally, he secured an All India Rank (AIR) of 9 in the NIPER Ph.D. entrance examination and has qualified multiple national-level pharmaceutical entrance tests, including GPAT 2016 and 2017. These achievements reflect his scholarly excellence and innovative research potential.
Publications
Dr. Salave has contributed significantly to peer-reviewed research with impactful publications. His selected works include:
-
Salave S et al. (2023). Peptide Engraftment on PEGylated Nanoliposomes for Bone Specific Delivery of PTH (1-34). Pharmaceutics, 15(2):608 – Cited by 12 articles.
-
Salave S et al. (2022). Anabolic Peptide-Enriched Stealth Nanoliposomes for Effective Anti-Osteoporotic Therapy. Pharmaceutics, 14(11):2417 – Cited by 18 articles.
-
Salave S et al. (2022). Encapsulation of Anabolic Peptide in Lipid Nano Vesicles for Osteoporosis. Current Protein and Peptide Science, 23(7):495-503 – Cited by 9 articles.
-
Salave S et al. (2023). Quantification of Anti-Osteoporotic Anabolic Peptide in Stealth Lipid Nanovesicles. Journal of AOAC International, 106(1):40-8 – Cited by 5 articles.
-
Rana D, Salave S et al. (2024). Quality-by-design based development of doxycycline hyclate–loaded polymeric microspheres. AAPS PharmSciTech, 25(3):49 – Cited by 3 articles.
-
Jadhav A, Salave S et al. (2023). Dexamethasone Loaded Ophthalmic Microemulsion. Drug Delivery Letters, 13 – Cited by 2 articles.
-
Salave S et al. (2022). Dual Targeting Anti-Osteoporotic Therapy through Nanotherapeutic Approaches. Pharmaceutical Nanotechnology, 10(5):384-92 – Cited by 7 articles.
These publications reflect his deep engagement with nanotechnology and drug delivery research, focusing on improving treatment outcomes through advanced delivery platforms.
Conclusion
Dr. Sagar Salave embodies all the essential qualities of a deserving recipient of the Research for Young Scientist Award—a deep commitment to research innovation, significant scholarly contributions, industrial acumen, leadership in the academic community, and a clear trajectory of future scientific impact. His interdisciplinary expertise and international exposure make him an outstanding role model for young researchers globally.